76 related articles for article (PubMed ID: 11562750)
1. Low incidence of genetic alterations of the p16CDKN2a in clear cell chondrosarcoma.
Park YK; Cho CH; Chi SG; Han CS; Ushigome S; Unni KK
Int J Oncol; 2001 Oct; 19(4):749-53. PubMed ID: 11562750
[TBL] [Abstract][Full Text] [Related]
2. Mutational alterations of the p16CDKN2A tumor suppressor gene have low incidence in mesenchymal chondrosarcoma.
Bae DK; Park YK; Chi SG; Lee CW; Unni KK
Oncol Res; 2000; 12(1):5-10. PubMed ID: 11061340
[TBL] [Abstract][Full Text] [Related]
3. Mutational alteration of the p16CDKN2a tumor suppressor gene is infrequent in Ewing's sarcoma.
Park YK; Chi SG; Kim YW; Park HR; Unni KK
Oncol Rep; 1999; 6(6):1261-6. PubMed ID: 10523693
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of p53 and absent genetic mutation in clear cell chondrosarcoma.
Park YK; Park HR; Chi SG; Ushigome S; Unni KK
Int J Oncol; 2001 Aug; 19(2):353-7. PubMed ID: 11445851
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.
van Beerendonk HM; Rozeman LB; Taminiau AH; Sciot R; Bovée JV; Cleton-Jansen AM; Hogendoorn PC
J Pathol; 2004 Mar; 202(3):359-66. PubMed ID: 14991902
[TBL] [Abstract][Full Text] [Related]
6. How is the mutational status for tumor suppressors p53 and p16(INK4A) in MFH of the bone?
Taubert H; Berger D; Hinze R; Meye A; Würl P; Hogendoorn PC; Holzhausen HJ; Schmidt H; Rath FW
Cancer Lett; 1998 Jan; 123(2):147-51. PubMed ID: 9489481
[TBL] [Abstract][Full Text] [Related]
7. Changes in p14(ARF) do not play a primary role in human chondrosarcoma tissues.
Asp J; Brantsing C; Benassi MS; Inerot S; Sangiorgi L; Picci P; Lindahl A
Int J Cancer; 2001 Sep; 93(5):703-5. PubMed ID: 11477582
[TBL] [Abstract][Full Text] [Related]
8. PTEN mutation is rare in chondrosarcoma.
Lin C; Meitner PA; Terek RM
Diagn Mol Pathol; 2002 Mar; 11(1):22-6. PubMed ID: 11854598
[TBL] [Abstract][Full Text] [Related]
9. Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues.
Asp J; Sangiorgi L; Inerot SE; Lindahl A; Molendini L; Benassi MS; Picci P
Int J Cancer; 2000 Mar; 85(6):782-6. PubMed ID: 10709095
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma.
Bovée JV; Cleton-Jansen AM; Kuipers-Dijkshoorn NJ; van den Broek LJ; Taminiau AH; Cornelisse CJ; Hogendoorn PC
Genes Chromosomes Cancer; 1999 Nov; 26(3):237-46. PubMed ID: 10502322
[TBL] [Abstract][Full Text] [Related]
11. P53 mutations in Ewing's sarcoma.
Park YK; Chi SG; Kim YW; Park HR; Unni KK
Oncol Rep; 2001; 8(3):533-7. PubMed ID: 11295075
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of p53 and rare genetic mutation in mesenchymal chondrosarcoma.
Park YK; Park HR; Chi SG; Kim CJ; Sohn KR; Koh JS; Kim CW; Yang WI; Ro JY; Ahn KW; Joo M; Kim YW; Lee J; Yang MH; Unni KK
Oncol Rep; 2000; 7(5):1041-7. PubMed ID: 10948336
[TBL] [Abstract][Full Text] [Related]
13. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma.
El-Naggar AK; Lai S; Clayman G; Lee JK; Luna MA; Goepfert H; Batsakis JG
Am J Pathol; 1997 Dec; 151(6):1767-74. PubMed ID: 9403727
[TBL] [Abstract][Full Text] [Related]
14. p53 mutations in chondrosarcoma.
Terek RM; Healey JH; Garin-Chesa P; Mak S; Huvos A; Albino AP
Diagn Mol Pathol; 1998 Feb; 7(1):51-6. PubMed ID: 9646035
[TBL] [Abstract][Full Text] [Related]
15. Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma.
Röpke M; Boltze C; Neumann HW; Roessner A; Schneider-Stock R
Pathol Res Pract; 2003; 199(6):437-44. PubMed ID: 12924447
[TBL] [Abstract][Full Text] [Related]
16. H-ras oncogene mutation in dedifferentiated chondrosarcoma: polymerase chain reaction-restriction fragment length polymorphism analysis.
Sakamoto A; Oda Y; Adachi T; Oshiro Y; Tamiya S; Tanaka K; Matsuda S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2001 Apr; 14(4):343-9. PubMed ID: 11301351
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the p16/MTS1-tumor suppressor gene in gastric cancer.
Günther T; Schneider-Stock R; Pross M; Manger T; Malfertheiner P; Lippert H; Roessner A
Pathol Res Pract; 1998; 194(12):809-13. PubMed ID: 9894245
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation.
Muscarella P; Melvin WS; Fisher WE; Foor J; Ellison EC; Herman JG; Schirmer WJ; Hitchcock CL; DeYoung BR; Weghorst CM
Cancer Res; 1998 Jan; 58(2):237-40. PubMed ID: 9443399
[TBL] [Abstract][Full Text] [Related]
19. Possible association of p53 overexpression and mutation with high-grade chondrosarcoma.
Dobashi Y; Sugimura H; Sato A; Hirabayashi T; Kanda H; Kitagawa T; Kawaguchi N; Imamura T; Machinami R
Diagn Mol Pathol; 1993 Dec; 2(4):257-63. PubMed ID: 8118603
[TBL] [Abstract][Full Text] [Related]
20. Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies.
Shiohara M; Spirin K; Said JW; Gombart AF; Nakamaki T; Takeuchi S; Hatta Y; Morosetti R; Tasaka T; Seriu T; Bartram C; Miller CW; Tomonaga M; Koeffler HP
Leukemia; 1996 Dec; 10(12):1897-900. PubMed ID: 8946928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
